Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Pharvaris N.V. - Ordinary Shares (NQ:PHVS)

21.59 -0.21 (-0.96%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 103,660
Open 21.80
Bid (Size) 21.00 (300)
Ask (Size) 34.22 (200)
Prev. Close 21.80
Today's Range 21.02 - 22.32
52wk Range 11.51 - 26.33
Shares Outstanding 33,816,459
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
From Pharvaris N.V.
Via GlobeNewswire
This Uber Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga

Performance

YTD
+16.5%
+16.5%
1 Month
-3.8%
-3.8%
3 Month
+6.2%
+6.2%
6 Month
+26.7%
+26.7%
1 Year
-13.7%
-13.7%

More News

Read More
Pharvaris NV (NASDAQ:PHVS) Reports Wider Q2 2025 Loss, Highlights Clinical Trial Progress
Via Chartmill
Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Proposed Public Offering of Ordinary Shares
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Annual Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Outlines 2025 Strategic Priorities
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Host Virtual Investor Event on October 23, 2024
From Pharvaris N.V.
Via GlobeNewswire

Frequently Asked Questions

Is Pharvaris N.V. - Ordinary Shares publicly traded?
Yes, Pharvaris N.V. - Ordinary Shares is publicly traded.
What exchange does Pharvaris N.V. - Ordinary Shares trade on?
Pharvaris N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Pharvaris N.V. - Ordinary Shares?
The ticker symbol for Pharvaris N.V. - Ordinary Shares is PHVS on the Nasdaq Stock Market
What is the current price of Pharvaris N.V. - Ordinary Shares?
The current price of Pharvaris N.V. - Ordinary Shares is 21.59
When was Pharvaris N.V. - Ordinary Shares last traded?
The last trade of Pharvaris N.V. - Ordinary Shares was at 11/07/25 04:00 PM ET
What is the market capitalization of Pharvaris N.V. - Ordinary Shares?
The market capitalization of Pharvaris N.V. - Ordinary Shares is 730.10M
How many shares of Pharvaris N.V. - Ordinary Shares are outstanding?
Pharvaris N.V. - Ordinary Shares has 730M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.